ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of direct lytic
agents (DLAs), including lysins and amurin peptides, as a new
modality for the treatment of life-threatening,
antibiotic-resistant infections, today announced the company’s
poster presentation of results from an ex vivo study of its amurin
peptide candidate, Aap2-M1, at the jointly sponsored American
Society of Microbiology and European Society of Clinical
Microbiology and Infectious Disease (ASM/ESCMID) Conference on Drug
Development to Meet the Challenge of Antimicrobial Resistance, to
be held from September 3-6, 2019, in Boston. In this study, a
clinically relevant concentration of Aap2-M1 eradicated
Stenotrophomonas biofilms formed inside hemodialysis catheters
removed from patients with suspected catheter-related bloodstream
infections in the clinical care setting. Stenotrophomonas is an
opportunistic, multidrug-resistant, Gram-negative pathogen, which
is associated with high morbidity and mortality in hospitalized
patients, particularly immunocompromised and debilitated
individuals, and is a recognized pathogen for cystic fibrosis
patients. These new data provide the first evidence of the activity
of an amurin peptide against biofilm formed by a deadly
Gram-negative pathogen in the setting of human infection.
In addition, Cara Cassino, M.D., Chief Medical
Officer and Executive Vice President of Research and Development,
will be speaking on the development of ContraFect’s lead
therapeutic candidate, exebacase, for the treatment of
Staphylococcus aureus bacteremia, including endocarditis.
Presentation Details:
Poster Presentation
Title: Amurin Peptide App2-M1
Eradicates Stenotrophomonas Biofilms Formed on Hemodialysis
Catheters in the Setting of Human Infection Poster Board
Number: 51Session Day &
Time: Wednesday, September 4, 2019, 8:30 a.m – 6:30
p.m. ETPresentation Time: Wednesday,
September 4, 2019, 4:25 p.m – 6:25 p.m. ET
Presentation Title:
Development of Exebacase (Lysin CF-301), a Direct Lytic Agent with
Potent Activity Against Staphylococcus
aureusSpeaker: Cara Cassino, M.D., Chief Medical
Officer and Executive Vice President of Research and
DevelopmentSession: The Road from Pre-Clinical to
Clinical for Non-Traditional TherapiesSession Day &
Time: Friday, September 6, 2019, 9:55 a.m – 11:55
a.m. ET
Following the meeting, the presentation poster
will be available on the ContraFect website.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of direct
lytic agents (DLAs), which include lysins and amurin peptides.
Lysins are a new therapeutic class of DLAs which are recombinantly
produced, antimicrobial proteins with a novel mechanism of action
associated with the rapid killing of target bacteria, eradication
of biofilms and synergy with conventional antibiotics. Amurin
peptides are new class of DLAs which exhibit broad-spectrum
activity against a wide range of antibiotic-resistant Gram-negative
pathogens, including Pseudomonas aeruginosa (P. aeruginosa),
Acinetobacter baumannii, and Enterobacter species. We believe that
the properties of our lysins and amurin peptides will make them
suitable for targeting antibiotic-resistant organisms, such as
methicillin-resistant Staph aureus (MRSA) and P. aeruginosa, which
can cause serious infections such as bacteremia, pneumonia and
osteomyelitis. We have completed a Phase 2 clinical trial for the
treatment of Staph aureus bacteremia, including endocarditis, with
our lead lysin candidate, exebacase (CF-301), which is the first
lysin to enter clinical studies in the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
About Exebacase (CF-301):
Exebacase (CF-301) is a recombinantly-produced
lysin (cell wall hydrolase enzyme) with potent bactericidal
activity against Staph aureus, a major cause of blood stream
infections (BSIs) also known as bacteremia. It has a novel, rapid,
and specific mechanism of bactericidal action against Staph aureus.
By targeting a conserved region of the cell wall that is vital to
bacteria, resistance is less likely to develop to exebacase. We
have completed a Phase 2 superiority design clinical study with
exebacase which evaluated its safety, tolerability, efficacy and PK
when used in addition to standard-of-care (SOC) antibiotics for the
treatment of Staph aureus bacteremia, including endocarditis, in
adult patients. In a pre-specified analysis of MRSA-infected
patients, the clinical responder rate at day 14 in patients treated
with exebacase was 42.8% higher than the clinical responder rate in
patients treated with SOC antibiotics alone (74.1% for patients
treated with exebacase compared to 31.3% for patients treated with
SOC antibiotics alone (p=0.010)). Additionally, among US MRSA
patients discharged alive from the hospital, the median length of
stay was reduced by four days and the 30-day all cause readmission
rate was reduced to 16.0% from 30.8% in patients treated with
exebacase. We believe exebacase has the potential to be a
first-in-class treatment for Staph aureus bacteremia.
Exebacase was licensed from The Rockefeller University and is being
developed at ContraFect.
Forward-Looking
Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding planned data
presentations, the Company’s ability to address life threatening
infections using its therapeutic product candidates from its DLA
platform, whether the properties of the Company’s lysins will
make them suitable for targeting antibiotic-resistant organisms,
such as Staph aureus and P. aeruginosa, and the potential for
exebacase to be a first-in-class treatment for Staph aureus
bacteremia. Forward-looking statements are statements that are not
historical facts, nor assurances of future performance. Instead,
they are based on ContraFect’s current beliefs, expectations and
assumptions regarding the future of its business, future plans,
strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent risks,
uncertainties and changes in circumstances that are difficult to
predict and many of which are beyond ContraFect’s control,
including those detailed under the caption “Risk Factors” in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations
Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024